What is the recommended weight‑based dosing regimen for heparin (unfractionated and low‑molecular‑weight) in a patient, including adjustments for renal impairment and low body weight?

Weight-Based Heparin Dosing Recommendations

For unfractionated heparin (UFH), use an 80 U/kg IV bolus (maximum 4000 U) followed by 18 U/kg/hour infusion (maximum 1000 U/hour initially), adjusted to maintain aPTT 1.5-2.0 times control. For low-molecular-weight heparin (LMWH), use enoxaparin 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily, with dose reductions required for renal impairment 1, 2.

Unfractionated Heparin (UFH)

Standard Dosing

The weight-based approach is critical because body weight is the predominant variable affecting heparin's anticoagulant effect 3. The FDA-approved regimen specifies:

• IV bolus: 80 U/kg (maximum 4000 U for patients >50 kg)
• Continuous infusion: 18 U/kg/hour (maximum 1000 U/hour for patients >55 kg)
• Target aPTT: 1.5-2.0 times control (approximately 50-70 seconds), corresponding to anti-factor Xa levels of 0.3-0.7 IU/mL 1, 2

For subcutaneous administration when IV access is problematic, use 333 U/kg initial dose followed by 250 U/kg twice daily 1.

Monitoring Requirements

Check aPTT approximately every 4 hours initially, then at appropriate intervals once therapeutic 2. Monitor platelet counts every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients 1.

Dose Capping Considerations

The maximum doses (4000 U bolus, 1000 U/hour infusion) apply to patients weighing >50-55 kg. However, recent evidence suggests these caps may lead to inadequate anticoagulation in obese patients 4. For patients >150 kg, consider using larger absolute doses (U/hour) but reduced weight-based doses (U/kg/hour) - approximately 11.6 U/kg/hour rather than 18 U/kg/hour 4.

Low-Molecular-Weight Heparin (LMWH)

Enoxaparin Dosing

Treatment dose:

• 1 mg/kg subcutaneously every 12 hours (preferred by most guidelines)
• Alternative: 1.5 mg/kg once daily 1

Prophylactic dose:

• 40 mg subcutaneously once daily (standard patients)
• Consider 30 mg once daily for patients <50 kg 5

Renal Impairment Adjustments

This is where LMWH dosing becomes critical. LMWHs are renally cleared and accumulate in renal dysfunction 1, 6:

• CrCl <30 mL/min:

  • Enoxaparin: Reduce to 1 mg/kg once daily (instead of twice daily) 1, 7
  • Alternative: Avoid LMWH entirely and use UFH instead 1
  • Fondaparinux: Contraindicated 1

• CrCl 30-50 mL/min:

  • Use caution with enoxaparin; consider dose reduction to 75% or anti-Xa monitoring 7
  • Fondaparinux preferred over enoxaparin in this range 7

• CrCl >50 mL/min: Standard dosing without adjustment 1

Calculate creatinine clearance using the Cockcroft-Gault equation, as this was used in clinical trials 6, 8.

Low Body Weight Adjustments

For patients <50 kg:

• Enoxaparin prophylaxis: Consider reducing from 40 mg to 30 mg once daily 5
• Treatment doses: Use standard weight-based dosing (1 mg/kg) but monitor closely for bleeding
• Fondaparinux: Use 5 mg once daily (weight-tiered dosing) 1

Obesity Considerations

For morbidly obese patients (BMI ≥40 kg/m² or weight >190 kg):

• Use total body weight for treatment dose calculations 6, 8
• Consider anti-Xa monitoring 4 hours post-dose (target 0.5-1.0 IU/mL for twice daily, 1.0-2.0 IU/mL for once daily) 6
• Prophylactic doses may need to be increased in patients with BMI ≥40 kg/m² 6

Dalteparin Dosing

Treatment: 200 U/kg subcutaneously once daily (maximum 18,000 U) 1, 9

Prophylaxis: 5,000 U once daily 9, 10

Renal impairment: Use caution if CrCl <30 mL/min; avoid tinzaparin in patients >70 years with renal insufficiency 10

Fondaparinux Dosing

Weight-tiered approach 1:

• <50 kg: 5 mg once daily
• 50-100 kg: 7.5 mg once daily

• 100 kg: 10 mg once daily

Absolute contraindication: CrCl <30 mL/min 1

Caution: CrCl 30-50 mL/min, weight <50 kg, or age >75 years 10

Anti-Xa Monitoring

Do not monitor routinely 11, 12. Reserve anti-Xa testing for:

• Morbid obesity (weight >190 kg)
• Severe renal impairment (CrCl <30 mL/min) with prolonged LMWH use (>10 days)
• Pregnancy
• Extremes of age with altered pharmacokinetics 11, 6, 12

Sampling timing: Draw 4 hours post-dose for twice-daily regimens, 4-6 hours post-dose for once-daily regimens 11, 12.

Target ranges:

• Twice daily dosing: 0.5-1.0 IU/mL
• Once daily dosing: 1.0-2.0 IU/mL 13

Common Pitfalls

1. Using ideal body weight instead of actual body weight for LMWH - always use actual body weight for treatment doses 6, 8

2. Failing to reassess renal function - CrCl can change rapidly in acute illness; recalculate if clinical status changes 6, 12

3. Applying dose caps too liberally in obese patients - this leads to under-anticoagulation and increased VTE risk 4, 14

4. Using LMWH in severe renal impairment without dose adjustment - this significantly increases bleeding risk 1, 6

5. Routine anti-Xa monitoring - this adds cost without improving outcomes in most patients 11, 12